Nonpartisan civic infrastructure
AllCiv·Legis1
·

H.R. 3327

BillFederalHouseIn Committee
Drug Price Transparency for Medicare Patients Act of 2019
About This Bill
Committee
Latest Action · June 19, 2019
Referred to the Subcommittee on Health.
Congress
116th (2019–2021)
Introduced
June 18, 2019
Cosponsors (1)
1D 0R
View PDF ↗

Summary

Highlight any text to annotate
Drug Price Transparency for Medicare Patients Act of 2019 This bill provides statutory authority for the Centers for Medicare & Medicaid Services rule titled "Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency," published on May 10, 2019. The rule requires direct-to-consumer television advertisements for covered drugs and biologics under Medicare and Medicaid to include the list price of a 30-day supply or for a typical course of treatment, if the list price is at least $35 per month. The rule takes effect July 9, 2019.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.